New experimental drug for Alzheimer's found helpful
While not a breakthrough, drug appears to stabilize brain plaque
While it failed to stop mental decline in Alzheimer's patients, a new experimental drug signaled a potential benefit that if given earlier, appears to stabilize brain plaque. According to researchers, some patients on the drug had more stable levels of brain plaque and less evidence of nerve damage as compared to patients on a placebo.
Brain imaging coupled with spinal fluid tests are 'very encouraging' and suggest the drug was 'doing something to the biology of the disease.'
"We're very disappointed that we were not able to come up with a treatment to provide to our dementia patients in the near term," Dr. Reisa Sperling, director of the Alzheimer's center at Brigham and Women's Hospital in Boston said.
Brain imaging coupled with spinal fluid tests are "very encouraging" and suggest the drug was "doing something to the biology of the disease."
The drug will now go forward in people with mild mental impairment -- or those who show plaque on brain imaging but have not yet developed symptoms of dementia. People with mild cognitive impairment, about 15 to 20 percent a year will develop Alzheimer's disease.
Thirty-five million people worldwide are estimated to have dementia, and Alzheimer's is the most common manifestation. About 5 million in the U.S. have Alzheimer's. Current medicines such as Aricept and Namenda just temporarily ease symptoms. There is no known cure.
Previous studies of the drug study have proved to be disappointing, including results reported earlier on bapineuzumab. The drug failed to slow mental decline or improve activities of daily living for patients with mild to moderate Alzheimer's in studies in both the United States and Canada.
Bapineuzumab is designed to attach and help clear amyloid, the material that makes up the sticky plaque that clogs patients' brains, harming nerve cells and impairing memory and thought. Doctors are still unaware if amyloid is a cause or just a symptom of Alzheimer's, but many companies are testing drugs to try to remove it.
Sperling's study involved test subjects with a gene that raises the risk of developing the disease. Dr. Stephen Salloway, a neurologist at Brown Medical School in Providence, R.I., led the other study of people without the gene.
Both researchers have consulted for the companies that make the drug and presented results Tuesday at a neurology conference in Stockholm.
Brain imaging on a subset of patients in Sperling's study found 9 percent less amyloid in those on bapineuzumab compared to those on a dummy treatment. The drug group had stable levels while the others developed more plaque.
© 2012, Catholic Online. Distributed by NEWS CONSORTIUM.
- - -
Pope Benedict XVI's Prayer Intentions for January 2013
General Intention: The Faith of Christians. That in this Year of Faith Christians may deepen their knowledge of the mystery of Christ and witness joyfully to the gift of faith in him.
Missionary Intention: Middle Eastern Christians. That the Christian communities of the Middle East, often discriminated against, may receive from the Holy Spirit the strength of fidelity and perseverance.
Keywords: Alzheimer's dementia, tests, bapineuzumab
Rate This Article
Leave a Comment
More Health News
- Forget printing guns, doctors use 3D printer to save baby
- Is it really that simple? - Research suggests ordinary vitamin C kills drug-resistant TB
- Chamomile tea can be refreshing treat - as well as a safeguard against cancer, researchers say
- HIV resurgent among Navajo tribe as deadly cases spike
- UK to give cancer patients genetic analysis just like Angelina Jolie
- Vitamin D found beneficial in treating asthma symptoms
- Study: Depressed women in 40s, 50s suffer more than twice for stroke risk
- Some experts say it's biologically possible to clone a human
- Study: Women live longer than men as their immune systems age more slowly
- Fr. Paul Schenck: Finding Living Faith on Catechetical Sunday
- The Movie Yellow: Incest as 'Normal' and Cassavates's Slides Into the World of Woes
- The Chicago School Teachers Strike Reveals the Need For School Choice
- The Sexual Barbarians and the Dissolution of Culture
- The Happy Priest Challenges Us to Ask: Who is Jesus to Me?
- Michael Coren on Canadian Public Schools: Teachers, leave those kids alone
- We Cannot Ignore Our Consciences: Cardinal Dolan On Religious Liberty
- In the Face of Danger, Successor of Peter Travels to Lebanon as a Messenger of Peace
- Reflections on the Dignity and Vocation of Women: Who or What?